Related Experiment Video
Updated: Nov 25, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide-induced serious RR interval prolongation (longest interval >5.0 s) in multiple myeloma patient with
Li Huang1, Yuemin Kuang1, Zhiyong Jiang1
1Department of Hematology, Jinhua People's Hospital, No. 228 Xinhua Street, Jinhua, Zhejiang, 32100, China.
Abstract:
Primary secondary tumor increased recently with the use of immunomodulatory drugs in patients with multiple myeloma (MM). However, MM with prior diagnosis of primary secondary tumor is relatively rare. In this study, we reported an MM patient with prior diagnosis of rectal cancer. In brief, an 85-year-old man was first diagnosed with rectal cancer. Given the age, heart failure and small-cell hypochromic anemia (hemoglobin level: 54 g/L), rectal cancer resection was not advised and symptomatic treatments were performed (including sufficient iron supplementation). Eight months later, the patient was diagnosed with MM due to worsening anemia. Anemia and heart failure were corrected after three cycles of treatment with thalidomide, dexamethasone and capecitabine. Radical resection of rectal carcinoma (Hartmann) was finally performed due to acute abdominal distension. Meanwhile, RR interval prolongation (longest interval >5.0 s) and atrial fibrillation occurred in the fifth cycle treatment. One month after discontinuation of thalidomide, RR interval returned to normal range, while atrial fibrillation developed into persistent atrial fibrillation.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Therapeutic Drug Monitoring: Affecting Factors
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules

